Vantage Wealth’s Gossamer Bio GOSS Stock Holding History

Vantage Wealth’s Portfolio GOSS Stock Details GOSS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-50,000	Closed	-$63K	–	37
2023 Q1	$63K	Buy	+50,000	New	+$95.7K	0.02%	35

Other funds holding GOSS

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vantage Wealth's GOSS Position: Q2 2023 in Review

Vantage Wealth sold out of Gossamer Bio (GOSS) in Q2 2023, closing a stake of 50,000 shares — an estimated $63K sold.

Vantage Wealth first reported a position in GOSS in Q1 2023 and held it in 1 quarter. The position peaked at $63K in Q1 2023. 99 funds tracked by Wall St. Rank hold GOSS as of Q2 2023.

Vantage Wealth reported no remaining Gossamer Bio position as of Q2 2023 after selling out during the quarter.
Vantage Wealth sold 50,000 Gossamer Bio shares in Q2 2023, an estimated $63K.
Vantage Wealth first reported a position in Gossamer Bio in Q1 2023 and held it in 1 quarter.
Vantage Wealth's Gossamer Bio position peaked at $63K in Q1 2023.
99 funds tracked by Wall St. Rank held Gossamer Bio as of Q2 2023.

Based on Vantage Wealth's 13F filing for Q2 2023, filed 24 Jul 2023.